Announced Mon, 6 Apr · 23:37 IST
Filing of compliance certificates for Q4 FY26
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+32.6%1-day move
₹18.86
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+32.6+37.8+29.0+26.5+32.8+35.0+16.4+6.0+30.4+20.8
Up moveDown movePending
AI summary
Beryl Drugs Ltd has submitted three regulatory compliance certificates to BSE for the quarter ended 31 March 2026. These include: (1) a Reg 74(5) certificate from its registrar Adroit Corporate Services confirming dematerialised securities were properly processed, listed and registered within 15 days; (2) a Reg 7(3) compliance certificate confirming physical and electronic share transfer facilities are maintained; and (3) a Reg 57(5) non-applicability certificate. All filings are routine SEBI LODR requirements.
Likely market impact
Routine regulatory filing with no impact on business, financials, or share price.